SOURCE: Insight Pharma Reports

Insight Pharma Reports

June 07, 2016 11:00 ET

Cancer Immunotherapy: Immune Checkpoint Inhibitors, Cancer Vaccines, and Adoptive T-Cell Therapies

The Rising Potential for the Newest and Most Promising of Cancer Treatments

NEEDHAM, MA--(Marketwired - June 07, 2016) - Insight Pharma Reports, a division of Healthtech Publishing, provides the life science sciences community the Cancer Immunotherapy Report, a report focusing the three principal types of therapeutics that have become the major focuses of research and development in cancer immunotherapy; Checkpoint inhibitors, Therapeutic anticancer vaccines and Adoptive cellular immunotherapy.

The Cancer Immunotherapy Report also includes a survey on adoptive immunotherapy for cancer and three expert interviews with three high-end professors, researchers and CEOs:

  • Adil Daud, MD, Clinical Professor, Department of Medicine (Hematology/Oncology), University of California at San Francisco (UCSF); Director, Melanoma Clinical Research, UCSF Helen Diller Family Comprehensive Cancer Center.
  • Matthew Lehman, Chief Executive Officer, Prima BioMed (a therapeutic cancer vaccine company with headquarters in Sydney, Australia).
  • Marcela Maus, MD, PhD, the Director of Translational Medicine and Early Clinical Development, Translational Research Program, Abramson Cancer Center, University of Pennsylvania in Philadelphia.

For more information on these reports visit: InsightPharmaReports.com/Cancer-Immunotherapy-Report

About Insight Pharma Reports (www.insightpharmareports.com)
Insight Pharma Reports, a division of Healthtech Publishing, is the premier life sciences information provider offering unparalleled coverage of key issues in drug discovery and development. The reports are used by leading pharmaceutical, biotech, diagnostic, and other life science companies to keep abreast of the latest developments in pharmaceutical R&D and their potential applications and business impacts. The reports are written by experts in consulting and industry, and are supported by hundreds of hours of primary and secondary research. Insight Pharma Reports provide comprehensive coverage of salient issues in a concise, well-organized format.

About Healthtech Publishing (www.healthtechpublishing.com)
Healthtech Publishing, a division of Cambridge Healthtech Institute, provides the life science communities with business critical intelligence through research reports and digital news, helping decision makers to gain competitive advantage and make strategic decisions. Our portfolio consists of Insight Pharma Reports' vast research reports collection and three niche digital subscription products: Bio-IT World, Clinical Informatics News and Diagnostics World.

Contact Information